Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
Provention Bio’s shares skyrocketed 262% to $24.27 in pre-market trading today, on the news that French pharma major Sanofi had made a takeover bid for the US biotech. 13 March 2023
Pharmaceutical
Shares of US drug developer Intercept Pharmaceuticals closed almost 14% lower at $16.12 on Friday, after it revealed that the US regulator will hold an advisory committee meeting to review its re-submitted approval request for its investigational non-alcoholic steatohepatitis (NASH) treatment obeticholic acid (OCA). 13 March 2023
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Daybue (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. 11 March 2023
Biotechnology
Some $230 million has now been raised by Ring Therapeutics, a life sciences company founded by Flagship Pioneering with the aim of revolutionizing gene therapy with its commensal virome platform. 10 March 2023
Biotechnology
Shares of MacroGenics were up 10.9% at $6.10 in early trading today, after the biopharmaceutical company revealed that it has entered into an agreement to sell its royalty interest on future global net sales of Tzield (teplizumab-mzwv) to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million. 9 March 2023
Biotechnology
Cambridge, USA-based clinical-stage biotech QurAlis Corporation has closed an oversubscribed $88 million Series B financing, bringing the total funds raised by the company0 to $143.5 million. 9 March 2023
Biotechnology
UK biotech Redx Pharma added to its woes, announcing that top-line results of its Phase II program were not sufficient enough to support the development of its RXC004 treatment as a monotherapy. 8 March 2023
Biotechnology
Italian drugmaker Chiesi and Swedish biotech Affibody have agreed a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using the latter company’s technology. 8 March 2023
Biotechnology
The strategic venture capital unit of US healthcare giant Johnson & Johnson (NYSE: JNJ) has put its weight behind a $100 million boost for a new precision medicine company. 8 March 2023
Biotechnology
Venture capital-backed Capsida Biotherapeutics has appointed Susan Catalano as chief scientific officer. 8 March 2023
Biotechnology
Protagonist Therapeutics’ shares closed up a massive 52% at $23.09 yesterday, after it announced positive top-line results from the FRONTIER 1 Phase IIb clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis. 8 March 2023
Biotechnology
US clinical-stage cancer biotech Volastra Therapeutics, which is focused on exploiting chromosomal instability (CIN), today announced completion of the in-licensing of Amgen’s sovilnesib (AMG650), an oral, first-in-class small molecule inhibitor of KIF18A. 7 March 2023
Biotechnology
Shares of Aclaris Therapeutics closed down almost 45% at $7.07 yesterday, as the company said its zunsemetinib did not meet its primary and secondary efficacy endpoints in a Phase IIa study evaluating the investigational drug in patients with moderate to severe hidradenitis suppurativa. 7 March 2023
Biotechnology
Shares of UK cell therapy specialist Adaptimmune Therapeutics and Cambridge, USA-based TCR² Therapeutics moved in opposite directions this morning, as they announced plans to merge. 6 March 2023
Pharmaceutical
UK-based drug developer ImmuPharma has signed an initial collaboration agreement on the company's peptide technology, with Orano. 6 March 2023
Pharmaceutical
While Esperion announced a statistically-significant outcome for heart med Nexletol (bempedoic acid) over the weekend, markets were less than impressed with the size of the treatment benefit. 6 March 2023
Biosimilars
South Korea’s Celltrion Healthcare saw its shares gain more than 7% to 57,700 Korean won on Friday, after it presented new data for its novel subcutaneous infliximab treatment, CT-P13 SC, also known as Remsima, at the European Crohn’s and Colitis Organization congress last week. 6 March 2023
Biotechnology
USA-based clinical stage biotech Mineralys Therapeutics (Nasdaq: MLYS) announced positive data from the Target-HTN Phase II study that demonstrated clinically-meaningful blood pressure reduction with once-daily dosing of lorundrostat. 6 March 2023
Biotechnology
Shares of Boston, USA-based biotech Praxis Precision Medicines sank almost 66% to $1.00 on Friday, after it said it would move its most advanced experimental drug into late-stage human testing, despite reporting that ulixacaltamide failed to meet the main goal of a mid-stage clinical trial. 4 March 2023
Biotechnology
A merger between Flamingo Therapeutics and Dynacure will create a new oncology company, retaining the Flamingo name, advancing lead candidates danvatirsen and FTX-001. 3 March 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze